Claritev (NYSE:CTEV) CEO Buys $174,645.00 in Stock

Claritev (NYSE:CTEV) CEO Travis Dalton bought 4,500 shares of the stock in a transaction on Thursday, August 27th. The stock was purchased at an average price of $38.81 per share, for a total transaction of $174,645.00. Following the completion of the purchase, the chief executive officer owned 50,372 shares of the company’s stock, valued at approximately $1,954,937.32. This trade represents a 9.81% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Travis Dalton also recently made the following trade(s):

• On Friday, August 28th, Travis Dalton purchased 1,950 shares of Claritev stock. The shares were purchased at an average price of $38.48 per share, with a total value of $75,036.00.

Claritev Stock Performance

Shares of CTEV opened at $39.98 on Thursday. The business has a 50-day moving average of $31.81 and a 200 day moving average of $25.14. Claritev has a fifty-two week low of $11.50 and a fifty-two week high of $74.07. The firm has a market cap of $677.66 million, a P/E ratio of -2.35 and a beta of 0.88.

Claritev (NYSE:CTEV) last released its quarterly earnings data on Friday, August 7th. The company reported $1.41 EPS for the quarter, beating the consensus estimate of ($4.10) by $5.51. The business had revenue of $257.48 million for the quarter. As a group, research analysts predict that Claritev will post -15.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on CTEV shares. Piper Sandler reiterated an “overweight” rating and issued a $73.00 price objective on shares of Claritev in a research note on Wednesday, August 12th. Barclays restated an “overweight” rating and set a $40.00 target price (up from $28.00) on shares of Claritev in a research report on Thursday, August 20th. Canaccord Genuity Group raised their price target on Claritev from $37.00 to $43.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Citigroup reiterated a “buy” rating and issued a $45.00 price target (up from $40.00) on shares of Claritev in a research report on Monday, August 10th. Finally, Wells Fargo & Company boosted their price objective on Claritev from $22.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 12th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $44.83.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CTEV. Arini Captial Management Ltd purchased a new stake in shares of Claritev in the fourth quarter worth $64,291,000. Public Investment Fund purchased a new position in Claritev during the second quarter worth about $43,703,438. Beach Point Capital Management LP increased its stake in Claritev by 77.4% in the 4th quarter. Beach Point Capital Management LP now owns 755,002 shares of the company’s stock worth $32,276,000 after acquiring an additional 329,424 shares during the last quarter. Vanguard Group Inc. bought a new position in Claritev in the 3rd quarter worth about $27,483,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Claritev by 17.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 262,318 shares of the company’s stock valued at $11,214,000 after acquiring an additional 39,845 shares in the last quarter. Institutional investors own 87.15% of the company’s stock.

Claritev Company Profile

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.